Long term use of ticagrelor in patients with prior heart attack: ticagrelor plus aspirin versus aspirin monotherapy
ABSTRACT Review of: Bonaca MP, Bhatt DL, Cohen M, et al. Long term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791 1800. This Practice Pearl reviews the recent study Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared With Placebo on a Background of Aspirin Thrombolysis in Myocardial Infarction 54 (PEGASUS TIMI 54) It challenges the current standard of care of 12 months of dual antiplatelet followed by aspirin indefinitely. The study demonstrated that patients who received ticagrelor, either the 60 mg or 90 mg twice daily plus aspirin, showed a decreased risk of cardiovascular death, myocardial infarction, or stroke. The PEGASUS TIMI 54 trial also proved that the benefit of ticagrelor was seen early and continued to accrue over time, with a median of 33 months of follow up, meaning that the benefit persists over time. It is important to note that both doses of the ticagrelor were associated with higher incidence of bleeding, but the rates of fatal bleeding did not show any difference between the ticagrelor or placebo.
Postgraduate medicine